BY & LARGE PEPTIDES

TRIPLE-RECEPTOR AGONIST · INVESTIGATIONAL

Reta 40mg

Retatrutide · 40mg vial



RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY CONSUMPTION · NOT FOR SELF-ADMINISTRATION

Retatrutide is a single investigational molecule designed to activate three receptors: GIP, GLP-1 and glucagon. These pathways influence appetite, glucose handling and energy balance.

PRICING · PER UNIT

Mix & match any vials — 2–4 −10%, 5+ −15%

RETAIL 1 UNIT	2–4 −10%	5+ −15%
R998	R898	R848

HOW IT WORKS

The two incretin signals act on nutrient and appetite pathways, while glucagon adds a separate metabolic signal. It is being studied as a once-weekly treatment in controlled clinical trials.

RESEARCH CONTEXT

Phase 2 and phase 3 studies are evaluating obesity and metabolic disease. Lilly states that retatrutide remains investigational; results from a trial do not establish a protocol for unapproved vials.

VIAL CONTENTS & HANDLING

- 40mg retatrutide
- Single lyophilised vial

Quality & sourcing. Sourced from established manufacturers who test using HPLC analysis. COA available on request — **ask us on WhatsApp ↗**

Storage: keep unopened lyophilised vials in a cool, dark place. Once reconstituted, store in the fridge at 2–8°C and use within 2 months.

RESEARCH REFERENCE DOSAGE

40mg vial · 3ml water · 13.33mg/ml

LEVEL	AMOUNT	U100 UNITS	FREQUENCY
Beginner	2mg	**15 units**	Once weekly or split 2× weekly · any time
Intermediate	4–6mg	**30–45 units**	Once weekly or split 2× weekly · any time
Advanced	8–12mg	**60–90 units**	Once weekly or split 2× weekly · any time

Fixed 3ml · U100 device (1 unit = 0.01ml). For split weekly schedules, use half the listed full-amount units per administration. Research reference only—not human-use guidance.

Dosing status: No approved beginner dose or consumer titration schedule. Clinical-trial dose levels are study-design details, not instructions for these vials.

REFERENCES

- NEJM — Triple–Hormone-Receptor Agonist Retatrutide for Obesity (2023)
- Lilly — What to know about retatrutide (reviewed September 2026)